Skip to main
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is focused on developing its lead product candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH), a condition with no currently approved therapies, which positions the company to potentially capture a significant market share. The clinical trial results indicate that lanifibranor is unique in achieving both MASH resolution and fibrosis improvement within 24 weeks, with nearly 42% of participants showing fibrosis improvement compared to only 24% in the placebo group, suggesting a strong therapeutic profile. Additionally, partnership revenues with AbbVie and BI provide financial stability while the potential for lanifibranor to serve as a complementary therapy in combination treatments could accelerate its adoption and enhance prospects for success in the evolving NASH treatment landscape.

Bears say

Inventiva SA reported a significant net loss of €175.9 million, translating to a loss of €1.62 per share, which raises concerns about its financial stability and future operations. The company is facing considerable risks, including potential clinical trial failures, delays in development timelines, and challenges in accessing favorable equity capital, all of which could hinder its ability to execute planned operations. Furthermore, the competitive landscape in NASH treatment is problematic, as currently approved therapies have shown modest efficacy in key areas such as liver histology, raising doubts about the market potential for Inventiva's lead candidate, lanifibranor.

Inventiva S.A. (IVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Inventiva S.A. (IVA) has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.